Archive for the ‘Bone Marrow Stem Cells’ Category

Dog Arthritis helped with Dogs Own Adult Stem Cells
Arthritis in dogs can be helped with dogs OWN adult stem cells http://www.adult-stemcells-blog.com .. see stem cell nutrition options in tablets,capsules and granules, to release millions more of your dogs own bone marrow stem cells into his bloodstream to renew your sick dog with arthritis or other aging and health problems Witness another sick and aging dog being helped with his own stem cells and how to get more stem cells repairing Your sick dog WITHOUT Extractions.. and with NO Injections.. http://www.ejmorris.bizFrom:EJ MorrisViews:28 0ratingsTime:05:10More inPets Animals

Read more from the original source:
Dog Arthritis helped with Dogs Own Adult Stem Cells - Video

[RMS] Bone Marrow Stem Cell - OSSRON
Ossron is cultured autologous bone cells for bone formation. Ossron is performed by three stages : harvesting bone marrow from a patient #39;s own, cell culturing in stem cell processing center, and implanting the cultured bone cells into defect sites. Bone Marrow Stem Cell [BMSC] Bone marrow cells have shown an osteogenic potential. Only a small aspiration biopsy of bone marrow from the iliac crest is required to obtain these cells. Bone marrow stem cells are the most potent bone regenerator with abundant cell numbers, high viabilites, and highly expressed osteogenic activites. Bone marrow stem cells are able to generate tissue other than bone. These cells can be isolated, expanded in culture, and stimulated to differentiate into osteoblasts, adipocytes, chondrocytes, myocytes, neuronal cells and a variety of other connective tissue.From:SewonCellontechViews:1 0ratingsTime:06:24More inHowto Style

Read more:
[RMS] Bone Marrow Stem Cell - OSSRON - Video

Stem Cell : cervical vertebral stenotic myleopathy case - Blood stem cells
Atassia is a disease that affects the nervous system. In this specific case the horse was ten years old, and the diagnosis had been given when he was about a year old and over the years it had worsened as do most neurological pathologies. The fact that the horse improved by 70% over two months means that the stem cells that I use have the power to change themselves into nerve cells. This confirms " in vivo" that we have adult pluripotent stem cells, which, unlike fat and bone marrow stem cells, can change themselves into nervous tissue. We have some published papers that credit us with the discovery of pluripotent receptors in blood stem cells obtained "in vitro" with our patented system. In this first video the horse is totally uncoordinated and for months it had been impossible to ride him because the horse risked falling with the rider on top. You can see the notable rear muscle mass #39; atrophy.From:marcopolettiniengViews:34 1ratingsTime:04:55More inScience Technology

See more here:
Stem Cell : cervical vertebral stenotic myleopathy case - Blood stem cells - Video

Public release date: 19-Oct-2012 [ | E-mail | Share ]

Contact: Kim Polacek kim.polacek@moffitt.org 813-745-7408 H. Lee Moffitt Cancer Center & Research Institute

Claudio Anasetti, M.D., chair of the Department of Blood & Marrow Transplant at Moffitt Cancer Center, and colleagues from 47 research sites in the Blood and Marrow Transplant Clinical Trials Network conducted a two-year clinical trial comparing two-year survival probabilities for patients transplanted with peripheral blood stem cells or bone marrow stem cells from unrelated donors. The goal was to determine whether graft source, peripheral blood stem cells or bone marrow, affects outcomes in unrelated donor transplants for patients with leukemia or other hematologic malignancies.

Fifty transplant centers in the United States and Canada participated in this phase III study, which randomized 278 patients to receive bone marrow and 273 patients to receive peripheral blood stem cells as the graft source for transplant. The results of the study are in the Oct. 18 issue of The New England Journal of Medicine.

According to the trial analyses, there were no observed differences in overall survival, relapse, non-relapse mortality, or acute graft-versus-host disease (GHVD) between the patients receiving peripheral blood stem cells or bone marrow stem cells from unrelated donors. GVHD is a serious and often deadly post-transplant complication that occurs when the newly transplanted donor cells attack the transplant recipient's body. While engraftment was faster in patients receiving peripheral blood stem cells, there was a higher incidence of overall chronic GVHD in these patients (53 percent) than in those transplanted with bone marrow stem cells (40 percent). Patients receiving transplants of peripheral blood stem cells from unrelated donors also had a higher incidence of chronic GVHD affecting multiple organs (46 percent) than patients who received bone marrow stem cells (31 percent).

"Although peripheral blood stem cells from related donors have demonstrated clinical benefits, our trial demonstrates that when these stem cells originate from unrelated donors, they are not superior to bone marrow stem cells in terms of patient survival, and they increase the risk for chronic GVHD," said Anasetti, lead study author. "More effective strategies to prevent GVHD are needed to improve outcomes for all patients receiving unrelated donor transplants."

Peripheral blood stem cells are stem cells originally found in the bone marrow that have been moved into the blood stream by a special regimen of drugs. Unlike bone marrow stem cells, which must be extracted from the bones in an operating room, peripheral blood stem cells are more easily obtained through apheresis, a process similar to regular blood donation, which collects the peripheral blood stem cells through a tube inserted in a vein. A critical step before the transplant involves finding a donor that is tissue matched to the recipient.

About one-third of patients who need a peripheral blood stem cell or bone marrow transplant for treatment of leukemia or another blood disease are able to secure a related donor. According to the National Marrow Donor Program, for the 70 percent who cannot find a donor within their family, most will be able to find an unrelated donor. Because the majority of transplant patients need cells from unrelated donors, it's necessary to better understand the risks associated with transplants of unrelated donor cells.

Clinical trials on related donor transplants have demonstrated that peripheral blood stem cell transplants in patients with leukemia and other blood diseases result in better engraftment, lower relapse rates, and increased survival compared with transplants with bone marrow stem cells. However, those trials also found that peripheral blood stem cell transplants carry an increased risk of GVHD. Patients who survive early post-transplant may develop chronic GVHD, a disabling condition managed with long-term immunosuppressant therapy.

Many transplant centers are increasingly using peripheral blood stem cells as a source for adult stem cells because of their superiority in clinical trials that have directly compared outcomes between peripheral blood stem cells and bone marrow stem cells from related donors. However, there has not been a comparative study of the two transplant sources that has prospectively analyzed patient outcomes in unrelated donor transplants.

Go here to see the original:
Moffitt researcher says no survival advantage with peripheral blood stem cells versus bone marrow

ScienceDaily (Oct. 19, 2012) Claudio Anasetti, M.D., chair of the Department of Blood & Marrow Transplant at Moffitt Cancer Center, and colleagues from 47 research sites in the Blood and Marrow Transplant Clinical Trials Network conducted a two-year clinical trial comparing two-year survival probabilities for patients transplanted with peripheral blood stem cells or bone marrow stem cells from unrelated donors. The goal was to determine whether graft source, peripheral blood stem cells or bone marrow, affects outcomes in unrelated donor transplants for patients with leukemia or other hematologic malignancies.

Fifty transplant centers in the United States and Canada participated in this phase III study, which randomized 278 patients to receive bone marrow and 273 patients to receive peripheral blood stem cells as the graft source for transplant. The results of the study are in the Oct. 18 issue of The New England Journal of Medicine.

According to the trial analyses, there were no observed differences in overall survival, relapse, non-relapse mortality, or acute graft-versus-host disease (GHVD) between the patients receiving peripheral blood stem cells or bone marrow stem cells from unrelated donors. GVHD is a serious and often deadly post-transplant complication that occurs when the newly transplanted donor cells attack the transplant recipient's body. While engraftment was faster in patients receiving peripheral blood stem cells, there was a higher incidence of overall chronic GVHD in these patients (53 percent) than in those transplanted with bone marrow stem cells (40 percent). Patients receiving transplants of peripheral blood stem cells from unrelated donors also had a higher incidence of chronic GVHD affecting multiple organs (46 percent) than patients who received bone marrow stem cells (31 percent).

"Although peripheral blood stem cells from related donors have demonstrated clinical benefits, our trial demonstrates that when these stem cells originate from unrelated donors, they are not superior to bone marrow stem cells in terms of patient survival, and they increase the risk for chronic GVHD," said Anasetti, lead study author. "More effective strategies to prevent GVHD are needed to improve outcomes for all patients receiving unrelated donor transplants."

Peripheral blood stem cells are stem cells originally found in the bone marrow that have been moved into the blood stream by a special regimen of drugs. Unlike bone marrow stem cells, which must be extracted from the bones in an operating room, peripheral blood stem cells are more easily obtained through apheresis, a process similar to regular blood donation, which collects the peripheral blood stem cells through a tube inserted in a vein. A critical step before the transplant involves finding a donor that is tissue matched to the recipient.

About one-third of patients who need a peripheral blood stem cell or bone marrow transplant for treatment of leukemia or another blood disease are able to secure a related donor. According to the National Marrow Donor Program, for the 70 percent who cannot find a donor within their family, most will be able to find an unrelated donor. Because the majority of transplant patients need cells from unrelated donors, it's necessary to better understand the risks associated with transplants of unrelated donor cells.

Clinical trials on related donor transplants have demonstrated that peripheral blood stem cell transplants in patients with leukemia and other blood diseases result in better engraftment, lower relapse rates, and increased survival compared with transplants with bone marrow stem cells. However, those trials also found that peripheral blood stem cell transplants carry an increased risk of GVHD. Patients who survive early post-transplant may develop chronic GVHD, a disabling condition managed with long-term immunosuppressant therapy.

Many transplant centers are increasingly using peripheral blood stem cells as a source for adult stem cells because of their superiority in clinical trials that have directly compared outcomes between peripheral blood stem cells and bone marrow stem cells from related donors. However, there has not been a comparative study of the two transplant sources that has prospectively analyzed patient outcomes in unrelated donor transplants.

The study was funded by the National Heart, Lung and Blood Institute (U10HL069294), the National Cancer Institute and the National Marrow Donor Program.

Share this story on Facebook, Twitter, and Google:

Follow this link:
No survival advantage with peripheral blood stem cells versus bone marrow, study suggests

Critical Limb Trials Update
Lower limb amputation is a reality for thousands of people every year in South Carolina. Roper St. Francis Healthcare is leading the way in a clinical trial utilizing bone marrow stem cells to save limbs.From:RoperStFrancisViews:24 0ratingsTime:01:31More inScience Technology

Follow this link:
Critical Limb Trials Update - Video

Neil Riordan PhD - Stem Cell Therapy for Spinal Cord Injury || Stem Cell Treatments (Part 2 of 5)
Case studies of spinal cord injury patients treated with CD34+ and mesenchymal stem cells harvested from human umbilical cord Wharton #39;s jelly and cord blood, animal studies using mesenchymal stem cells, immunosuppression requirements in allogeneic stem cell treatments, intrathecal and intravenous administration of autologous bone marrow stem cells in spinal cord injury patients, and the role adult stem cell trophic factors in tissue regeneration.From:cellmedicineViews:623 5ratingsTime:12:57More inScience Technology

Here is the original post:
Neil Riordan PhD - Stem Cell Therapy for Spinal Cord Injury || Stem Cell Treatments (Part 2 of 5) - Video

Stem Cell Therapy for Critical Limb Ischemia - YouTube.flv
Dr. Michael Murphy discusses a previous trial using bone marrow stem cells, a clinical trial based upon research sponsored by Cryptic Masons Medical Research Foundation and ICVBM.From:CMMRF2012Views:69 1ratingsTime:01:39More inPeople Blogs

Here is the original post:
Stem Cell Therapy for Critical Limb Ischemia - YouTube.flv - Video

Dr.Mohamad Ghoneim
Dr.Mohamed Ahmed Ghoneim, MD (MD Hon.), Emeritus: Professor of Urology Mansoura University, Mansoura, Egypt. Dr.Ghoneim talks at the 2nd GCCTX11 Congress in Riyadh, Saudi Arabia,on October 4th 2011 about "Transplantation of Insulin producing cells derived from human Bone Marrow Stem Cells did Control."From:saudiorgantransplantViews:77 0ratingsTime:29:51More inScience Technology

See the rest here:
Dr.Mohamad Ghoneim - Video

Coast To Coast AM - 2011-11-15 - Regenerative Medicine / Dulce Base (Full Show)
Date: 11-15-11 Host: George Noory Guests: Anthony F. Sanchez, Christian Wilde In the first half, researcher Christian Wilde talked about the emerging field of regenerative medicine, and how scientists are actually building replacement body parts with stem cells. He announced that Dr. Richard Burt at Northwestern University #39;s School of Medicine has been successfully using patients own bone marrow stem cells to treat a variety of autoimmune diseases like Lupus, and Type 1 Diabetes. It may be possible to expand human lifespan up to around 150 years, Wilde declared, now that replacement organs such as kidneys and livers can be grown in a matter of 6-8 weeks. He cited an instance where new stem cells were injected into the cadaver heart of a rat, and in a few days it started beating again. And, he added, at the Univ. of Pittsburgh, a Marine who lost his right hand, has had a successful transplant of a cadaver hand. Wilde also spoke about heart health, and the importance of taking homocysteine and CRP (C-Reactive Protein) tests in order to monitor cardiac issues and inflammation. Supplements such as turmeric can reduce inflammation and protect against some cancers, he noted. -------------------------- In the latter half, software engineer and UFO researcher, Anthony F. Sanchez, presented details about an underground base in Dulce, New Mexico, and its connection to the Greys. Much of his information comes from "Colonel X," a retired military whistleblower, who wishes to remain ...From:PIGAMOUSViews:267 5ratingsTime:02:33:31More inNonprofits Activism

See the article here:
Coast To Coast AM - 2011-11-15 - Regenerative Medicine / Dulce Base (Full Show) - Video

Science Talk: Myelodysplastic Syndromes (MDS) Linked to Abnormal Stem Cells
http://www.einstein.yu.edu - July 2, 2012 - Researchers at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center have found that abnormal bone marrow stem cells drive the development of myelodysplastic syndromes (MDS). The findings published online July 2 in the journal Blood. See accompanying release http://www.einstein.yu.eduFrom:EinsteinCollegeofMedViews:212 1ratingsTime:02:59More inScience Technology

See the article here:
Science Talk: Myelodysplastic Syndromes (MDS) Linked to Abnormal Stem Cells - Video

Stem Cell Therapy - How Stem Cells Helped Emery with Pain and more!
Bone marrow stem cells helped Emery M. after having pain in his foot and other minor problems. He came to Dr. David Steenblock for adult stem cell treatments and did wonderfully. To find out more about bone marrow stem cells and how legal stem cells are done here in the US call Dr. Steenblock #39;s office: 1-800-300-1063.From:STEMCELLinfoViews:37 0ratingsTime:02:00More inScience Technology

Excerpt from:
Stem Cell Therapy - How Stem Cells Helped Emery with Pain and more! - Video

Stem cells for critical limb ischemia (NAPLES Study).m4v
This is the procedure of intra arterial autologous transplant of bone marrow stem cells for the treatment of critical limb ischemia according to NAPLES Study.From:Alessandro SchiavettaViews:47 0ratingsTime:01:16More inScience Technology

See the original post here:
Stem cells for critical limb ischemia (NAPLES Study).m4v - Video

Stem Cell Therapy And Tissue Engineering For Cardiovascular Repair
xxsurl.com Stem Cell Therapy And Tissue Engineering For Cardiovascular Repair Ventricular Remodeling in Ischemic Cardiomyopathy.- Myocardial Regeneration: Which Cell and Why.- Cardiac Stem Cells for Myocardial Regeneration.- A Historic Recapitulation of Myoblast Transplantation.- Myoblast Cell Transplantation Preclinical Studies.- Skeletal Myoblasts: The European Experience.- Skeletal Myoblasts: The US Experience.- Progenitor Cells for Cardiac Regeneration.- Bone Marrow Derived Stem Cell for Myocardial Regeneration: Preclinical Experience.- Bone Marrow Derived Stem Cell for Myocardial Regeneration: Clinical Experience, Surgical Delivery.- Autologous Mononuclear Bone Marrow Cell Transplantation for Myocardial Infarction: The German Experience.- Autologous Mononuclear Bone Marrow Cell Transplantation for Myocardial Infarction: The Spanish Experience.- Mobilizing Bone Marrow Stem Cells for Myocardial Repair after Acute Myocardial Infarction.- Percutaneous Myoblast Transplantation: Steps in Translational Research.- A Porcine Model of Myocardial Infarction for Evaluation of Cell Transplantation.- Tissue Engineering for Myocardial Regeneration.- The Role of PET Scan in Stem Cell Therapy.- The Measurement of Systolic Function in the Mammalian Heart.- Electrophysiological Aspects of Cell Transplantation.- Regulatory Considerations in Manufacturing, Product Testing, and Preclinical Development of Cellular Products for Cardiac Repair.- Appendix: Catheter Descriptions.- Index. EAN ...From:maurinecooper3Views:56 0ratingsTime:00:12More inPeople Blogs

Link:
Stem Cell Therapy And Tissue Engineering For Cardiovascular Repair - Video

Own Bone Marrow Adult Stem Cells Renewed Heart Attack Patient
Proactive Stem cell options to renew hearts with own bone marrow stem cells .. http://www.EJMorris.biz Your own bone marrow stem cells help repair aging and damaged hearts and other organs. Many stem cell procedures are performed in India, and other international countries. Some adult stem cell releasing.. extracting .. and stem cell injection procedures are performed in the USA. Investigate all your stem cell nutrition options.. including Naturally Releasing MILLIONS more Stem Cells from your Bone Marrow within 60 MINUTES of consuming 2 patented adult stem cell nutrition capsules. Investigate a proactive wellness lifestyle by releasing MILLIONS more of YOUR OWN adult stem cells from your bone marrow EVERY DAY with adult stem cell nutrition capsules. Your body is indeed a Miracle.. and your own adult stem cells constitute Your body #39;s own RENEWAL SYSTEM to help in anti-aging and rejuvenation of not only your heart .. but ALL your organs, tissues and muscles. See VIDEO of patented stem cell nutrition including capsules, tablets granules,powders and serums.. httpFrom:EJ MorrisViews:43 0ratingsTime:04:17More inScience Technology

Read the rest here:
Own Bone Marrow Adult Stem Cells Renewed Heart Attack Patient - Video

Releasing Her Own Adult Stem Cells Renewed Lisa Ray
Stem cell options for releasing more bone marrow stem cells .. http://www.EJMorris.biz Lisa Ray #39;s own bone marrow stem cells helped repair her body. Some stem cell procedures are performed in India, and some adult stem cell releasing.. extracting .. and stem cell injection procedures are performed in the USA. Investigate all your stem cell nutrition options..including Naturally Releasing MILLIONS more Stem Cells from your Bone Marrow within 60 MINUTES of consuming 2 patented adult stem cell nutrition capsules. Investigate your body #39;s own RENEWAL SYSTEM, using your OWN Bone Marrow Adult Stem Cells for repair and rejuvenation.From:EJ MorrisViews:63 0ratingsTime:01:01More inScience Technology

Continued here:
Releasing Her Own Adult Stem Cells Renewed Lisa Ray - Video

Release Millions More Bone Marrow Stem Cells.. Your Body #39;s Renewal System
Witness Proactive Bone Marrow Stem Cell option Videos here.. http://www.EJMorris.biz See adult stem cell animation of renewing your body tissues and organs with your own bone marrow stem cells .. http Your own bone marrow stem cells help repair aging and damaged tissues, muscles, bones ,hearts and other organs. Many stem cell procedures are performed in India, and other international countries. Some adult stem cell releasing.. extracting .. and stem cell injection procedures are performed in the USA. Investigate all your stem cell nutrition options.. including Naturally Releasing 3 to 4 MILLION more Stem Cells from your Bone Marrow within 60 MINUTES of consuming 2 patented adult stem cell nutrition capsules. Investigate a proactive wellness lifestyle by releasing MILLIONS more of YOUR OWN adult stem cells from your bone marrow EVERY DAY with adult stem cell nutrition capsules. Your body is indeed a Miracle.. and your own adult stem cells constitute Your body #39;s own RENEWAL SYSTEM to help in anti-aging and rejuvenation of not only your heart .. but ALL your organs, tissues and muscles. See VIDEO of patented stem cell nutrition including capsules, tablets granules, powders and serums.. http://www.EJrecommends.comFrom:EJ MorrisViews:25 0ratingsTime:06:27More inScience Technology

More here:
Release Millions More Bone Marrow Stem Cells.. Your Body's Renewal System - Video

Stem Cell Doctors from India and Stem Cell Options
Review stem cell doctors and stem cell nutrition options from India ..www.EJrecommends.com .. then investigate how your own bone marrow stem cells help repair aging and damaged tissues, muscles, bones ,hearts and other organs. Many stem cell procedures are performed in India, and other international countries. Some adult stem cell releasing.. extracting .. and stem cell injection procedures are performed in the USA. Investigate all your stem cell nutrition options.. including Naturally Releasing 3 to 4 MILLION more Stem Cells from your Bone Marrow within 60 MINUTES of consuming 2 patented adult stem cell nutrition capsules. Investigate a proactive wellness lifestyle by releasing MILLIONS more of YOUR OWN adult stem cells from your bone marrow EVERY DAY with adult stem cell nutrition capsules. Your body is indeed a Miracle.. and your own adult stem cells constitute Your body #39;s own RENEWAL SYSTEM to help in anti-aging and rejuvenation of not only your heart .. but ALL your organs, tissues and muscles. See VIDEO of patented stem cell nutrition including capsules, tablets granules, powders and serums.. httpFrom:EJ MorrisViews:30 0ratingsTime:04:34More inScience Technology

View post:
Stem Cell Doctors from India and Stem Cell Options - Video

2012 Ask the Experts -3 Facts about Stem Cell Research - Dr Megan Munsie
Dr Megan Munsie, Stem Cells Australia spoke on Hope, Hype and Reality: The Facts about Stem Cell Research. Megan explained that headlines about stem cells are often sensational and oversimplify where research is at. Present use of cord blood and bone marrow stem cells is limited to diseases of the blood -- #39;like for like #39;. Over the last 20 years researchers have been able to identify stem cells in the kidney, heart and brain, but these cannot be effectively harnessed for treatments yet. There is often a great focus on the potential therapeutic use for stem cells, but where stem cells are currently making a great scientific contribution is as a research tool for finding out more information about the disease itself, for example we can now look at how MND develops using stem cells in a petri dish. There is currently a long list of stem cell treatment companies even though treatments are yet unproven. A person considering stem cell treatment should speak with their neurologist first to better understand the context of the proposed treatment because the neurologist will be more impartial than a company #39;selling #39; the treatment. Booklets are available through Stem Cells Australia at http://www.stemcellsaustralia.edu.au to help with right questions to ask.From:mndnswViews:33 0ratingsTime:33:25More inNonprofits Activism

Go here to read the rest:
2012 Ask the Experts -3 Facts about Stem Cell Research - Dr Megan Munsie - Video

Stem Cell Treatment Helps Shoulder Pain!
Kurt came to Dr. Steenblock for help with his shoulder. Kurt did bone marrow stem cells and had great results with helping heal his right shoulder heal. Find out more by calling Dr. Steenblock #39;s office today at 1-800-300-1063.From:STEMCELLinfoViews:49 0ratingsTime:01:40More inScience Technology

See the original post here:
Stem Cell Treatment Helps Shoulder Pain! - Video

Dog Arthritis helped with Dogs Own Adult Stem Cells
Arthritis in dogs can be helped with dogs OWN adult stem cells http://www.adult-stemcells-blog.com .. see stem cell nutrition options in tablets,capsules and granules, to release millions more of your dogs own bone marrow stem cells into his bloodstream to renew your sick dog with arthritis or other aging and health problems Witness another sick and aging dog being helped with his own stem cells and how to get more stem cells repairing Your sick dog WITHOUT Extractions.. and with NO Injections.. http://www.ejmorris.bizFrom:EJ MorrisViews:28 0ratingsTime:05:10More inPets Animals

View post:
Dog Arthritis helped with Dogs Own Adult Stem Cells - Video

Stem Cell : cervical vertebral stenotic myleopathy case - Blood stem cells
Atassia is a disease that affects the nervous system. In this specific case the horse was ten years old, and the diagnosis had been given when he was about a year old and over the years it had worsened as do most neurological pathologies. The fact that the horse improved by 70% over two months means that the stem cells that I use have the power to change themselves into nerve cells. This confirms " in vivo" that we have adult pluripotent stem cells, which, unlike fat and bone marrow stem cells, can change themselves into nervous tissue. We have some published papers that credit us with the discovery of pluripotent receptors in blood stem cells obtained "in vitro" with our patented system. In this first video the horse is totally uncoordinated and for months it had been impossible to ride him because the horse risked falling with the rider on top. You can see the notable rear muscle mass #39; atrophy.From:marcopolettiniengViews:34 1ratingsTime:04:55More inScience Technology

See the article here:
Stem Cell : cervical vertebral stenotic myleopathy case - Blood stem cells - Video

[RMS] Bone Marrow Stem Cell - OSSRON
Ossron is cultured autologous bone cells for bone formation. Ossron is performed by three stages : harvesting bone marrow from a patient #39;s own, cell culturing in stem cell processing center, and implanting the cultured bone cells into defect sites. Bone Marrow Stem Cell [BMSC] Bone marrow cells have shown an osteogenic potential. Only a small aspiration biopsy of bone marrow from the iliac crest is required to obtain these cells. Bone marrow stem cells are the most potent bone regenerator with abundant cell numbers, high viabilites, and highly expressed osteogenic activites. Bone marrow stem cells are able to generate tissue other than bone. These cells can be isolated, expanded in culture, and stimulated to differentiate into osteoblasts, adipocytes, chondrocytes, myocytes, neuronal cells and a variety of other connective tissue.From:SewonCellontechViews:1 0ratingsTime:06:24More inHowto Style

Read more:
[RMS] Bone Marrow Stem Cell - OSSRON - Video

ScienceDaily (Oct. 19, 2012) Claudio Anasetti, M.D., chair of the Department of Blood & Marrow Transplant at Moffitt Cancer Center, and colleagues from 47 research sites in the Blood and Marrow Transplant Clinical Trials Network conducted a two-year clinical trial comparing two-year survival probabilities for patients transplanted with peripheral blood stem cells or bone marrow stem cells from unrelated donors. The goal was to determine whether graft source, peripheral blood stem cells or bone marrow, affects outcomes in unrelated donor transplants for patients with leukemia or other hematologic malignancies.

Fifty transplant centers in the United States and Canada participated in this phase III study, which randomized 278 patients to receive bone marrow and 273 patients to receive peripheral blood stem cells as the graft source for transplant. The results of the study are in the Oct. 18 issue of The New England Journal of Medicine.

According to the trial analyses, there were no observed differences in overall survival, relapse, non-relapse mortality, or acute graft-versus-host disease (GHVD) between the patients receiving peripheral blood stem cells or bone marrow stem cells from unrelated donors. GVHD is a serious and often deadly post-transplant complication that occurs when the newly transplanted donor cells attack the transplant recipient's body. While engraftment was faster in patients receiving peripheral blood stem cells, there was a higher incidence of overall chronic GVHD in these patients (53 percent) than in those transplanted with bone marrow stem cells (40 percent). Patients receiving transplants of peripheral blood stem cells from unrelated donors also had a higher incidence of chronic GVHD affecting multiple organs (46 percent) than patients who received bone marrow stem cells (31 percent).

"Although peripheral blood stem cells from related donors have demonstrated clinical benefits, our trial demonstrates that when these stem cells originate from unrelated donors, they are not superior to bone marrow stem cells in terms of patient survival, and they increase the risk for chronic GVHD," said Anasetti, lead study author. "More effective strategies to prevent GVHD are needed to improve outcomes for all patients receiving unrelated donor transplants."

Peripheral blood stem cells are stem cells originally found in the bone marrow that have been moved into the blood stream by a special regimen of drugs. Unlike bone marrow stem cells, which must be extracted from the bones in an operating room, peripheral blood stem cells are more easily obtained through apheresis, a process similar to regular blood donation, which collects the peripheral blood stem cells through a tube inserted in a vein. A critical step before the transplant involves finding a donor that is tissue matched to the recipient.

About one-third of patients who need a peripheral blood stem cell or bone marrow transplant for treatment of leukemia or another blood disease are able to secure a related donor. According to the National Marrow Donor Program, for the 70 percent who cannot find a donor within their family, most will be able to find an unrelated donor. Because the majority of transplant patients need cells from unrelated donors, it's necessary to better understand the risks associated with transplants of unrelated donor cells.

Clinical trials on related donor transplants have demonstrated that peripheral blood stem cell transplants in patients with leukemia and other blood diseases result in better engraftment, lower relapse rates, and increased survival compared with transplants with bone marrow stem cells. However, those trials also found that peripheral blood stem cell transplants carry an increased risk of GVHD. Patients who survive early post-transplant may develop chronic GVHD, a disabling condition managed with long-term immunosuppressant therapy.

Many transplant centers are increasingly using peripheral blood stem cells as a source for adult stem cells because of their superiority in clinical trials that have directly compared outcomes between peripheral blood stem cells and bone marrow stem cells from related donors. However, there has not been a comparative study of the two transplant sources that has prospectively analyzed patient outcomes in unrelated donor transplants.

The study was funded by the National Heart, Lung and Blood Institute (U10HL069294), the National Cancer Institute and the National Marrow Donor Program.

Share this story on Facebook, Twitter, and Google:

Go here to read the rest:
No survival advantage with peripheral blood stem cells versus bone marrow, study suggests

Public release date: 19-Oct-2012 [ | E-mail | Share ]

Contact: Kim Polacek kim.polacek@moffitt.org 813-745-7408 H. Lee Moffitt Cancer Center & Research Institute

Claudio Anasetti, M.D., chair of the Department of Blood & Marrow Transplant at Moffitt Cancer Center, and colleagues from 47 research sites in the Blood and Marrow Transplant Clinical Trials Network conducted a two-year clinical trial comparing two-year survival probabilities for patients transplanted with peripheral blood stem cells or bone marrow stem cells from unrelated donors. The goal was to determine whether graft source, peripheral blood stem cells or bone marrow, affects outcomes in unrelated donor transplants for patients with leukemia or other hematologic malignancies.

Fifty transplant centers in the United States and Canada participated in this phase III study, which randomized 278 patients to receive bone marrow and 273 patients to receive peripheral blood stem cells as the graft source for transplant. The results of the study are in the Oct. 18 issue of The New England Journal of Medicine.

According to the trial analyses, there were no observed differences in overall survival, relapse, non-relapse mortality, or acute graft-versus-host disease (GHVD) between the patients receiving peripheral blood stem cells or bone marrow stem cells from unrelated donors. GVHD is a serious and often deadly post-transplant complication that occurs when the newly transplanted donor cells attack the transplant recipient's body. While engraftment was faster in patients receiving peripheral blood stem cells, there was a higher incidence of overall chronic GVHD in these patients (53 percent) than in those transplanted with bone marrow stem cells (40 percent). Patients receiving transplants of peripheral blood stem cells from unrelated donors also had a higher incidence of chronic GVHD affecting multiple organs (46 percent) than patients who received bone marrow stem cells (31 percent).

"Although peripheral blood stem cells from related donors have demonstrated clinical benefits, our trial demonstrates that when these stem cells originate from unrelated donors, they are not superior to bone marrow stem cells in terms of patient survival, and they increase the risk for chronic GVHD," said Anasetti, lead study author. "More effective strategies to prevent GVHD are needed to improve outcomes for all patients receiving unrelated donor transplants."

Peripheral blood stem cells are stem cells originally found in the bone marrow that have been moved into the blood stream by a special regimen of drugs. Unlike bone marrow stem cells, which must be extracted from the bones in an operating room, peripheral blood stem cells are more easily obtained through apheresis, a process similar to regular blood donation, which collects the peripheral blood stem cells through a tube inserted in a vein. A critical step before the transplant involves finding a donor that is tissue matched to the recipient.

About one-third of patients who need a peripheral blood stem cell or bone marrow transplant for treatment of leukemia or another blood disease are able to secure a related donor. According to the National Marrow Donor Program, for the 70 percent who cannot find a donor within their family, most will be able to find an unrelated donor. Because the majority of transplant patients need cells from unrelated donors, it's necessary to better understand the risks associated with transplants of unrelated donor cells.

Clinical trials on related donor transplants have demonstrated that peripheral blood stem cell transplants in patients with leukemia and other blood diseases result in better engraftment, lower relapse rates, and increased survival compared with transplants with bone marrow stem cells. However, those trials also found that peripheral blood stem cell transplants carry an increased risk of GVHD. Patients who survive early post-transplant may develop chronic GVHD, a disabling condition managed with long-term immunosuppressant therapy.

Many transplant centers are increasingly using peripheral blood stem cells as a source for adult stem cells because of their superiority in clinical trials that have directly compared outcomes between peripheral blood stem cells and bone marrow stem cells from related donors. However, there has not been a comparative study of the two transplant sources that has prospectively analyzed patient outcomes in unrelated donor transplants.

Read the original here:
Moffitt researcher says no survival advantage with peripheral blood stem cells versus bone marrow